{"id":"W2103254744","doi":"10.3109/10428194.2012.660631","title":"Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"Vancouver General Hospital; Princess Margaret Cancer Centre","funders":"Takeda Oncology","keywords":"Cytarabine; Medicine; Myeloid leukemia; Neutropenia; Refractory (planetary science); Fms-Like Tyrosine Kinase 3; Phases of clinical research; Internal medicine; Pharmacology; Clinical trial; Chemotherapy; Chemistry; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001101885,0.001496532,0.001424998,0.0003160393,0.0003707402,0.0005652404,0.0005226339,0.0008088467,0.002558246],"category_scores_gemma":[0.0006760971,0.0004038032,0.0006244944,0.0002651365,0.0006617186,0.0005069079,0.0002945561,0.00192591,0.0006804675],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005431266,"about_ca_system_score_gemma":0.0008420062,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006583391,"about_ca_topic_score_gemma":0.002001156,"domain_scores_codex":[0.9997531,0.0001406534,0.000009762728,0.00003525776,0.00001787521,0.00004334823],"domain_scores_gemma":[0.9996479,0.00006544729,0.00006808617,0.00002000016,0.00001541573,0.0001832243],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7098265,0.05244707,0.008627488,0.0009987019,0.001036374,0.0005923182,0.0003782664,0.00318989,0.04980735,0.0004731966,0.008261156,0.1643617],"study_design_scores_gemma":[0.6332979,0.344788,0.01278324,0.00003961082,0.0002957621,0.0003958119,0.00003982057,0.001693558,0.003046047,0.0003212847,0.003274834,0.0000240502],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9915282,0.002778288,0.0005088904,0.0006267863,0.0001363229,0.001812132,0.0007346045,0.0001254637,0.00174941],"genre_scores_gemma":[0.9867603,0.002535317,0.001991039,0.001179371,0.0002485887,0.002071871,0.002141807,0.00002649635,0.003045239],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002558246,"threshold_uncertainty_score":0.008558214,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0167819574737144,"score_gpt":0.2891959538203783,"score_spread":0.2724139963466639,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}